Skip to main content
Clinical Trials/NCT00997438
NCT00997438CompletedPhase 1

Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis

Portland VA Medical Center4 sites in 1 country69 target enrollmentStarted: August 2010Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
69
Locations
4
Primary Endpoint
Lipoic Acid Levels

Study Overview

Brief Summary

The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis. This study will compare how subject's and healthy volunteers bodies absorb and break down the supplement. This information may help in developing new therapies.

Detailed Description

Subjects (healthy control, relapsing remitting MS and secondary progressive MS) will be recruited through patients of investigators at Portland VA Medical Center (PVAMC), Oregon Health & Science University (OHSU), and the community using flyers and word of mouth.

The following will occur during screening:

  • Medical History Questionnaire to include questions about drug and alcohol use
  • Self Administered Expanded Disability Status Scale (EDSS) Questionnaire (MS participants only)
  • Vital Signs (heart rate, respiratory rate, blood pressure) will be measured and recorded
  • Physical Exam (MS participants only unless necessary, based on the Medical History Questionnaire or vital signs, to ensure participant safety)
  • Neurological Exam (MS participants only unless necessary, based on the Medical History Questionnaire or vital signs, to ensure participant safety)
  • Weight
  • Urine pregnancy test, if applicable
  • Anemia testing by finger stick (approximately 1 drop)

The rest of the study involves

  • Blood draws before lipoic acid is given, 1 hour, 2 hours, 3 hours, 4 hours, 24 and 48 hours after LA is given (3 ½ tablespoons)
  • Subjects will receive breakfast before they take LA
  • Subjects will take 4 - 300 mg capsules of lipoic acid (LA) for a total of 1200mg with about 1 cup of water

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Lipoic Acid Levels

Time Frame: 48 hour

Plasma concentration of LA

cAMP Levels

Time Frame: 4 hours

Secondary Outcomes

  • RANTES Levels(48 hour)

Investigators

Sponsor Class
Fed
Responsible Party
Principal Investigator
Principal Investigator

Daniel Carr

Research Career Scientist

Portland VA Medical Center

Study Sites (4)

Loading locations...

Similar Trials